Is the Next Breakthrough in “Chemo Brain” Treatment Hiding in Diabetes Research? For cancer survivors, the battle often doesn’t end with remission. Chemotherapy-Induced Cognitive Impairment (CICI)โwidely known as “Chemo Brain”โremains one of the most debilitating long-term side effects of treatment, affecting memory, executive function, and attention. While the clinical impact is well-documented, therapeutic options remain […]
Posted in Featured, Neuroplasticity, Pharma and Medical Device 
Comments Off on “Chemo Brain” and Diabetes Research๐๐ก๐ฒ ๐๐๐ ๐๐ซ๐ข๐ ๐๐ฆ๐ข ๐ข๐ฌ ๐ญ๐ก๐ ๐๐๐๐ซ๐๐ญ ๐ญ๐จ ๐ “๐๐ข๐ฅ๐๐ง๐ญ” ๐๐๐๐๐ข๐ง๐ ๐๐๐๐๐๐จ๐ฅ๐ ๐๐ง ๐ฏ๐๐๐๐ข๐ง๐ ๐๐๐ฌ๐ข๐ ๐ง, “๐จ๐๐-๐ญ๐๐ซ๐ ๐๐ญ” ๐ซ๐๐ฌ๐ฉ๐จ๐ง๐ฌ๐๐ฌ ๐๐ซ๐ ๐ ๐ฉ๐๐ซ๐ฌ๐ข๐ฌ๐ญ๐๐ง๐ญ ๐ก๐ฎ๐ซ๐๐ฅ๐. ๐๐ก๐๐ง ๐ฐ๐ ๐ฎ๐ฌ๐ ๐ฉ๐ซ๐จ๐ญ๐๐ข๐ง-๐๐๐ฌ๐๐ ๐ฉ๐๐ซ๐ญ๐ข๐๐ฅ๐๐ฌ ๐ญ๐จ ๐๐๐ฅ๐ข๐ฏ๐๐ซ ๐๐ง ๐๐ง๐ญ๐ข๐ ๐๐ง, ๐ญ๐ก๐ ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ ๐ฌ๐ฒ๐ฌ๐ญ๐๐ฆ ๐จ๐๐ญ๐๐ง ๐ ๐๐ญ๐ฌ ๐๐ข๐ฌ๐ญ๐ซ๐๐๐ญ๐๐ ๐๐ง๐ ๐๐ญ๐ญ๐๐๐ค๐ฌ ๐ญ๐ก๐ ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฒ ๐ฏ๐๐ก๐ข๐๐ฅ๐ ๐ข๐ญ๐ฌ๐๐ฅ๐ ๐ข๐ง๐ฌ๐ญ๐๐๐ ๐จ๐ ๐ญ๐ก๐ ๐ฏ๐ข๐ซ๐ฎ๐ฌ. ๐๐๐ฐ ๐ซ๐๐ฌ๐๐๐ซ๐๐ก ๐๐ซ๐จ๐ฆ ๐๐๐ ๐๐ง๐ ๐๐๐ซ๐ข๐ฉ๐ฉ๐ฌ ๐๐๐ฌ๐๐๐ซ๐๐ก, ๐ฉ๐ฎ๐๐ฅ๐ข๐ฌ๐ก๐๐ ๐ข๐ง ๐๐๐ข๐๐ง๐๐, […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐๐ก๐ฒ ๐๐๐ ๐๐ซ๐ข๐ ๐๐ฆ๐ข ๐ข๐ฌ ๐ญ๐ก๐ ๐๐๐๐ซ๐๐ญ ๐ญ๐จ ๐ “๐๐ข๐ฅ๐๐ง๐ญ” ๐๐๐๐๐ข๐ง๐ ๐๐๐๐๐๐จ๐ฅ๐ ๐๐ง ๐ฏ๐๐๐๐ข๐ง๐ ๐๐๐ฌ๐ข๐ ๐ง,๐ก๐๐๐ ๐ฅ๐ฒ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐ฑ๐ ๐๐๐ฝ๐ถ๐น๐๐บ๐ฎ๐ฏ ๐ณ๐ผ๐ฟ ๐๐ผ๐๐ถ๐ป๐ผ๐ฝ๐ต๐ถ๐น๐ถ๐ฐ ๐๐ข๐ฃ๐: ๐ ๐๐ฒ๐ฒ๐ฝ ๐๐ถ๐๐ฒ ๐ถ๐ป๐๐ผ ๐๐ต๐ฒ ๐๐๐ถ๐ฑ๐ฒ๐ป๐ฐ๐ฒ ๐ฎ๐ป๐ฑ ๐๐ฐ๐ผ๐ป๐ผ๐บ๐ถ๐ฐ ๐๐ฎ๐๐ฒ ๐ง๐ต๐ฒ ๐จ๐’๐ ๐ก๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐๐ป๐๐๐ถ๐๐๐๐ฒ ๐ณ๐ผ๐ฟ ๐๐ฒ๐ฎ๐น๐๐ต ๐ฎ๐ป๐ฑ ๐๐ฎ๐ฟ๐ฒ ๐๐ ๐ฐ๐ฒ๐น๐น๐ฒ๐ป๐ฐ๐ฒ (๐ก๐๐๐) ๐ต๐ฎ๐ ๐ถ๐๐๐๐ฒ๐ฑ ๐ณ๐ถ๐ป๐ฎ๐น ๐ฑ๐ฟ๐ฎ๐ณ๐ ๐ด๐๐ถ๐ฑ๐ฎ๐ป๐ฐ๐ฒ ๐ฟ๐ฒ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐ฑ๐ถ๐ป๐ด ๐ฑ๐๐ฝ๐ถ๐น๐๐บ๐ฎ๐ฏ ๐ฎ๐ ๐ฎ๐ป ๐ฎ๐ฑ๐ฑ-๐ผ๐ป ๐บ๐ฎ๐ถ๐ป๐๐ฒ๐ป๐ฎ๐ป๐ฐ๐ฒ ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ ๐ณ๐ผ๐ฟ ๐ฎ ๐๐ฝ๐ฒ๐ฐ๐ถ๐ณ๐ถ๐ฐ, ๐ต๐ถ๐ด๐ต-๐ป๐ฒ๐ฒ๐ฑ ๐๐ข๐ฃ๐ ๐ฝ๐ผ๐ฝ๐๐น๐ฎ๐๐ถ๐ผ๐ป. ๐ง๐ต๐ถ๐ ๐บ๐ฎ๐ฟ๐ธ๐ ๐ฎ ๐ฝ๐ถ๐๐ผ๐๐ฎ๐น ๐๐ต๐ถ๐ณ๐ ๐๐ผ๐๐ฎ๐ฟ๐ฑ๐ ๐ฝ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐บ๐ฒ๐ฑ๐ถ๐ฐ๐ถ๐ป๐ฒ ๐ถ๐ป ๐ฐ๐ต๐ฟ๐ผ๐ป๐ถ๐ฐ ๐ฟ๐ฒ๐๐ฝ๐ถ๐ฟ๐ฎ๐๐ผ๐ฟ๐ ๐ฑ๐ถ๐๐ฒ๐ฎ๐๐ฒ. […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐ก๐๐๐ ๐ฅ๐ฒ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐ฑ๐ ๐๐๐ฝ๐ถ๐น๐๐บ๐ฎ๐ฏ ๐ณ๐ผ๐ฟ ๐๐ผ๐๐ถ๐ป๐ผ๐ฝ๐ต๐ถ๐น๐ถ๐ฐ ๐๐ข๐ฃ๐: ๐ ๐๐ฒ๐ฒ๐ฝ ๐๐ถ๐๐ฒ ๐ถ๐ป๐๐ผ ๐๐ต๐ฒ ๐๐๐ถ๐ฑ๐ฒ๐ป๐ฐ๐ฒ ๐ฎ๐ป๐ฑ ๐๐ฐ๐ผ๐ป๐ผ๐บ๐ถ๐ฐ ๐๐ฎ๐๐ฒMarket Access 2026: Transatlantic Pivot Toolkit A Strategic Resource for Founders & VCs Navigating the EU JSC & NHS Threshold Shifts Prepared by Michael A. S. Guth, Ph.D., J.D. | Strategic Systems Architect for High-Complexity Biologics, Drugs, and Device combinations Executive Summary The 2026 regulatory-access landscape has fundamentally shifted with two parallel developments: EU’s Joint […]
Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on The 2026 Transatlantic Market Access Pivot: An Architectural Framework๐๐ก๐ ๐ซ๐๐ฉ๐ข๐ ๐ฆ๐๐ญ๐ฎ๐ซ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐ฆ๐๐๐-๐๐๐ ๐ญ๐๐๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐ข๐ฌ ๐๐๐ญ๐๐ฅ๐ฒ๐ณ๐ข๐ง๐ ๐ ๐ง๐๐ฐ ๐๐ซ๐ ๐ข๐ง ๐ฏ๐๐๐๐ข๐ง๐จ๐ฅ๐จ๐ ๐ฒ, ๐ฆ๐จ๐ฏ๐ข๐ง๐ ๐๐๐๐ข๐ฌ๐ข๐ฏ๐๐ฅ๐ฒ ๐๐๐ฒ๐จ๐ง๐ ๐ฉ๐๐ง๐๐๐ฆ๐ข๐ ๐ซ๐๐ฌ๐ฉ๐จ๐ง๐ฌ๐. ๐๐ก๐ ๐๐๐๐ ๐จ๐ฎ๐ญ๐ฅ๐จ๐จ๐ค ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ ๐ฌ๐๐ฏ๐๐ซ๐๐ฅ ๐๐จ๐ง๐ฏ๐๐ซ๐ ๐๐ง๐ญ ๐ญ๐ซ๐๐๐ค๐ฌ: ๐๐ฅ๐๐ญ๐๐จ๐ซ๐ฆ ๐๐ฑ๐ฉ๐๐ง๐ฌ๐ข๐จ๐ง: ๐๐ก๐ ๐๐จ๐ซ๐ ๐ข๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐งโ๐ฎ๐ฌ๐ข๐ง๐ ๐๐๐๐ฌ ๐ญ๐จ ๐๐๐ฅ๐ข๐ฏ๐๐ซ ๐๐๐ ๐ฌ๐๐ช๐ฎ๐๐ง๐๐๐ฌ ๐๐ง๐๐จ๐๐ข๐ง๐ ๐ฉ๐ซ๐จ๐ญ๐๐ข๐ง ๐ข๐ฆ๐ฆ๐ฎ๐ง๐จ๐ ๐๐ง๐ฌโ๐ข๐ฌ ๐๐๐ข๐ง๐ ๐๐๐ฉ๐ฅ๐จ๐ฒ๐๐ ๐๐ ๐๐ข๐ง๐ฌ๐ญ ๐ก๐ข๐ฌ๐ญ๐จ๐ซ๐ข๐๐๐ฅ๐ฅ๐ฒ ๐ข๐ง๐ญ๐ซ๐๐๐ญ๐๐๐ฅ๐ ๐ฉ๐๐ญ๐ก๐จ๐ ๐๐ง๐ฌ. ๐ ๐จ๐ซ ๐๐๐, ๐ ๐๐ซ๐ฆ๐ฅ๐ข๐ง๐-๐ญ๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐ฌ๐ญ๐ซ๐๐ญ๐๐ ๐ข๐๐ฌ ๐ฐ๐ข๐ญ๐ก ๐ฌ๐๐ช๐ฎ๐๐ง๐ญ๐ข๐๐ฅ ๐ฆ๐๐๐ ๐๐จ๐จ๐ฌ๐ญ๐๐ซ๐ฌ ๐๐ข๐ฆ ๐ญ๐จ ๐ ๐ฎ๐ข๐๐ […]
Posted in Pharma and Medical Device Comments Off on ๐๐๐ฒ๐จ๐ง๐ ๐๐๐๐๐-๐๐: ๐๐ก๐ ๐๐๐ฑ๐ญ ๐
๐ซ๐จ๐ง๐ญ๐ข๐๐ซ๐ฌ ๐๐จ๐ซ ๐ฆ๐๐๐ ๐๐ง๐ ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฒ ๐๐ฅ๐๐ญ๐๐จ๐ซ๐ฆ๐ฌ ๐ข๐ง ๐๐ฅ๐จ๐๐๐ฅ ๐๐ฆ๐ฆ๐ฎ๐ง๐ข๐ณ๐๐ญ๐ข๐จ๐ง๐๐ต๐ฎ๐น๐น๐ฒ๐ป๐ด๐ฒ ๐๐ต๐ฒ ๐ฝ๐ฟ๐ฒ๐บ๐ถ๐๐ฒ ๐ผ๐ณ ๐ฐ๐ฒ๐น๐ฒ๐ฏ๐ฟ๐ฎ๐๐ถ๐ป๐ด ๐ป๐ผ๐ป-๐ถ๐ป๐ณ๐ฒ๐ฟ๐ถ๐ผ๐ฟ๐ถ๐๐ ๐ถ๐ป ๐ฎ ๐บ๐ฎ๐๐๐ฟ๐ฒ ๐บ๐ฎ๐ฟ๐ธ๐ฒ๐ ๐ฎ๐ป๐ฑ ๐พ๐๐ฒ๐๐๐ถ๐ผ๐ป ๐๐ต๐ฒ ๐ต๐ฒ๐ฎ๐น๐๐ต ๐ฒ๐ฐ๐ผ๐ป๐ผ๐บ๐ถ๐ฐ ๐ฟ๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น๐ฒ. ๐๐ฒ๐ฎ๐ฑ๐น๐ถ๐ป๐ฒ: ๐ ๐ก๐ฒ๐ ๐ฃ๐ถ๐น๐น ๐ณ๐ผ๐ฟ ๐๐๐ฉ: ๐๐ป๐ฐ๐ฟ๐ฒ๐บ๐ฒ๐ป๐๐ฎ๐น ๐๐ต๐ฎ๐ป๐ด๐ฒ ๐ผ๐ฟ ๐ฃ๐ฟ๐ถ๐ฐ๐ฒ๐ฑ ๐ฎ๐ ๐๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป? ๐๐ถ๐น๐ฒ๐ฎ๐ฑ’๐ ๐๐ฅ๐ง๐๐ฆ๐ง๐ฅ๐ฌ-๐ฎ ๐๐ฟ๐ถ๐ฎ๐น ๐๐ต๐ผ๐๐ ๐ถ๐๐ ๐ป๐ฒ๐ ๐๐๐/๐๐๐ก ๐๐ถ๐ป๐ด๐น๐ฒ-๐๐ฎ๐ฏ๐น๐ฒ๐ ๐ฟ๐ฒ๐ด๐ถ๐บ๐ฒ๐ป ๐ถ๐ ๐ป๐ผ๐ป-๐ถ๐ป๐ณ๐ฒ๐ฟ๐ถ๐ผ๐ฟ ๐๐ผ ๐ถ๐๐ ๐ผ๐๐ป ๐ฏ๐น๐ผ๐ฐ๐ธ๐ฏ๐๐๐๐ฒ๐ฟ, ๐๐๐๐ง๐๐ฅ๐ฉ๐ฌ, ๐ณ๐ผ๐ฟ ๐๐ถ๐ฟ๐ผ๐น๐ผ๐ด๐ถ๐ฐ๐ฎ๐น๐น๐ ๐๐๐ฝ๐ฝ๐ฟ๐ฒ๐๐๐ฒ๐ฑ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐. ๐ง๐ต๐ฒ ๐๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ฒ ๐ถ๐ ๐๐ผ๐๐ป๐ฑ, ๐ฏ๐๐ ๐ถ๐ ๐ฝ๐ฟ๐ผ๐บ๐ฝ๐๐ […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐๐ฅ๐ ๐ช๐ ๐ก๐ข๐ช ๐๐ก ๐ง๐๐ ๐๐จ๐ฆ๐๐ก๐๐ฆ๐ฆ ๐ข๐ ๐ฅ๐๐๐ ๐๐จ๐ฅ๐ฆ๐๐ก๐ “๐ก๐ข๐ก-๐๐ก๐๐๐ฅ๐๐ข๐ฅ?”The MajesTEC-3 results for teclistamab + daratumumab (Tec-Dara)ย in relapsed/refractory multiple myeloma (RRMM) aren’t just an incremental gainโthey represent a potential paradigm shift. The FDA’s concurrent award of aย priority review voucherย underscores its transformative potential. Let’s break down the data that’s changing the standard of care: ๐ฌ Unprecedented Efficacy in the 1-3 Prior Lines Setting: โขย PFS:ย Hazard Ratio […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara๐ ๐จ๐ซ ๐ฒ๐๐๐ซ๐ฌ, ๐ญ๐ก๐ ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐ซ๐๐ฅ๐ข๐๐ ๐จ๐ง ๐ญ๐ซ๐๐๐ข๐ญ๐ข๐จ๐ง๐๐ฅ ๐ฏ๐ข๐ซ๐ญ๐ฎ๐๐ฅ ๐ฌ๐๐ซ๐๐๐ง๐ข๐ง๐ ๐ญ๐จ ๐๐ข๐ง๐ ๐ง๐๐๐๐ฅ๐๐ฌ ๐ข๐ง ๐ญ๐ก๐ “๐๐๐ซ๐ค ๐๐๐ง๐จ๐ฆ๐” ๐ก๐๐ฒ๐ฌ๐ญ๐๐๐ค. ๐๐ฎ๐ญ ๐๐จ๐ซ ๐จ๐ซ๐ฉ๐ก๐๐ง ๐ญ๐๐ซ๐ ๐๐ญ๐ฌ ๐ฅ๐ข๐ค๐ ๐๐๐๐๐๐, ๐ฐ๐ก๐๐ซ๐ ๐ฅ๐ข๐ ๐๐ง๐ ๐๐ก๐๐ฆ๐ข๐ฌ๐ญ๐ซ๐ฒ ๐ข๐ฌ ๐ฎ๐ง๐๐๐๐ข๐ง๐๐, ๐ฐ๐ ๐ง๐๐๐ ๐ฆ๐จ๐ซ๐ ๐ญ๐ก๐๐ง ๐ ๐๐๐ญ๐ญ๐๐ซ ๐ฌ๐๐๐ซ๐๐ก ๐๐ง๐ ๐ข๐ง๐. ๐๐ ๐ง๐๐๐ ๐ ๐๐๐ง๐๐ซ๐๐ญ๐ข๐ฏ๐ ๐๐ง๐ ๐ข๐ง๐. ๐๐ฌ ๐ฉ๐๐ซ๐ญ ๐จ๐ ๐ฆ๐ฒ ๐ฅ๐๐ญ๐๐ฌ๐ญ “๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ข๐๐ฅ ๐๐ฅ๐ฎ๐๐ฉ๐ซ๐ข๐ง๐ญ” ๐๐จ๐ซ ๐๐ซ๐ฎ๐ ๐๐ข๐ฌ๐๐จ๐ฏ๐๐ซ๐ฒ ๐๐จ๐๐๐ฒ, ๐โ๐ฏ๐ ๐จ๐ฎ๐ญ๐ฅ๐ข๐ง๐๐ ๐ฐ๐ก๐ฒ […]
Posted in AI Governance, Neuroplasticity, Pharma and Medical Device Comments Off on ๐๐ก๐ฒ “๐๐ข๐ซ๐ญ๐ฎ๐๐ฅ ๐๐๐ซ๐๐๐ง๐ข๐ง๐ ” ๐ข๐ฌ ๐๐จ ๐๐จ๐ง๐ ๐๐ซ ๐๐ง๐จ๐ฎ๐ ๐ก ๐๐จ๐ซ ๐๐ซ๐ฉ๐ก๐๐ง ๐๐๐๐๐ฌ๐๐ก๐ “๐๐ฎ๐ซ๐ฉ๐ฅ๐ ๐๐ช๐ฎ๐ข๐ซ๐ซ๐๐ฅ” ๐๐๐ฅ๐๐ง๐ญ ๐๐๐ฉ Recruiters often call this the โpurple squirrelโ profile: a “unicorn” blending deep regulatory strategy, therapeutic area such as neurology research expertise, with a fundamental understanding of AI application.
Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐
๐ซ๐จ๐ฆ ๐๐ฌ๐ฌ๐ข๐ฌ๐ญ๐๐ง๐๐ ๐ญ๐จ ๐๐ ๐๐ง๐๐ฒ: ๐๐ก๐ฒ ๐๐ซ๐๐๐ข๐ฌ๐ข๐จ๐ง ๐๐๐ซ๐ ๐๐ข๐๐ง๐ญ๐ฌ ๐๐๐๐ ๐๐จ๐ฆ๐๐ข๐ง๐๐ ๐๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ/๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐ ๐๐ซ๐๐/๐๐ ๐๐ค๐ข๐ฅ๐ฅ๐๐ ๐๐๐ฅ๐๐ง๐ญBeyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy In my independent review of the CARES-310 trial (Camrelizumab-Rivoceranib), I analyzed a common pitfall in modern drug development: the reliance on 16-week primary endpoints to justify long-term therapeutic narratives. While a 16-week data cut can deliver a clean p-value for a regulatory […]
Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy